InnoCan Pharma Corporation reported earnings results for the second quarter and six months ended June 30, 2024. For the second quarter, the company reported sales was USD 8.64 million compared to USD 3.12 million a year ago. Net income was USD 0.337 million compared to net loss of USD 0.52 million a year ago. Basic earnings per share from continuing operations was USD 0.001 compared to basic loss per share from continuing operations of USD 0.002 a year ago. Diluted earnings per share from continuing operations was USD 0.001 compared to diluted loss per share from continuing operations of USD 0.002 a year ago.
For the six months, sales was USD 15.41 million compared to USD 4.68 million a year ago. Net loss was USD 1.43 million compared to USD 1.79 million a year ago. Basic loss per share from continuing operations was USD 0.005 compared to USD 0.007 a year ago.